ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • Live CE Webinar: Is Shorter Better? Exploring Shorter Durations of Therapy for Common Infections in Children and Adults

Live CE Webinar: Is Shorter Better? Exploring Shorter Durations of Therapy for Common Infections in Children and Adults

  • 27 Jun 2024
  • 1:00 PM - 2:00 PM (EDT)

Thursday, June 27, 2024
12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET


While there is no doubt about the benefits of appropriate use of antibiotics in bacterial infections, the effectiveness of antibiotics come at a price of adverse reactions, development of resistance, disturbance of the microbiome and the resultant cascade of harmful outcomes. In an effort to reduce inappropriately prolonged courses of antimicrobial therapy, numerous studies in the last decade have promoted shorter courses of antibiotic therapy for various infections. Unfortunately, antibiotic overprescribing is driven not only by the knowledge gaps in appropriate duration but also by the fear of perceived patient demand. Therefore, it is essential both to be well aware of the emerging data on shorter durations of antibiotic therapy as compared to common practice and/or guidelines and to recognize the challenges and clinical considerations in adopting shorter treatment courses when applying these data.

This activity will discuss durations of antimicrobial therapy and include audience polling throughout. Attendees will have an opportunity for Q&A at the end of the presentation.

Target Audience:

This activity was planned to meet the educational needs of infectious diseases pharmacists. The educational content is also relevant for other healthcare practitioners working in infectious diseases patient-care settings who are directly involved in treatment decisions.

Learning Objectives:

  • Discuss current guideline recommendations on duration of antibiotic treatment courses for commonly seen infections. 
  • Review available clinical data on shorter antibiotic courses for adult and pediatric patients. 
  • Describe challenges and considerations when implementing shorter courses of antibiotics. 
  • Identify appropriate patient populations for shorter antibiotic treatment durations of commonly seen infections.


Christine MacBrayne, PharmD, MSCS, BCIDP
Antimicrobial Stewardship Clinical Pharmacy Specialist & Clinical Pharmacy Manager – Network of Care
Department of Pharmacy
Children’s Hospital Colorado
Aurora, Colorado

Bryan P. White, PharmD, FIDSA, BCIDP
Infectious Diseases Clinical Pharmacist
University of Oklahoma Medical Center
Oklahoma City, OK



The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-24-012-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Knowledge
Activity Fee: SIDP Member: Free / Non-Member: $10

To receive CE credit, participants must view the CE content, complete a post-test, and complete an activity evaluation. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.


This activity is provided by SIDP. No external funding was received for this activity.


In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

  • Dr. MacBrayne has no financial relationship with an ineligible company to disclose. 
  • Dr. White has received research funding from Shionogi and serves as a consultant/advisor/speaker for Melinta Therapeutics.
  • SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.


Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software